Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 199

1.

The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.

Caldarone BJ, Paterson NE, Zhou J, Brunner D, Kozikowski AP, Westphal KG, Korte-Bouws GA, Prins J, Korte SM, Olivier B, Ghavami A.

J Pharmacol Exp Ther. 2010 Dec;335(3):762-70. doi: 10.1124/jpet.110.174011. Epub 2010 Sep 23.

PMID:
20864506
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor.

Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS.

Eur J Pharmacol. 2003 Feb 14;461(2-3):99-104.

PMID:
12586204
[PubMed - indexed for MEDLINE]
3.

Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS).

Liang Y, Shaw AM, Boules M, Briody S, Robinson J, Oliveros A, Blazar E, Williams K, Zhang Y, Carlier PR, Richelson E.

J Pharmacol Exp Ther. 2008 Nov;327(2):573-83. doi: 10.1124/jpet.108.143610. Epub 2008 Aug 8.

PMID:
18689611
[PubMed - indexed for MEDLINE]
Free Article
4.

The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: a microdialysis study in olfactory bulbectomized rats.

Prins J, Westphal KG, Korte-Bouws GA, Quinton MS, Schreiber R, Olivier B, Korte SM.

Pharmacol Biochem Behav. 2011 Jan;97(3):444-52. doi: 10.1016/j.pbb.2010.10.001. Epub 2010 Oct 8.

PMID:
20934452
[PubMed - indexed for MEDLINE]
5.

D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action.

Dutta AK, Ghosh B, Biswas S, Reith ME.

Eur J Pharmacol. 2008 Jul 28;589(1-3):73-9. doi: 10.1016/j.ejphar.2008.05.008. Epub 2008 May 20.

PMID:
18561912
[PubMed - indexed for MEDLINE]
6.

Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity.

Golembiowska K, Kowalska M, Bymaster FP.

Synapse. 2012 May;66(5):435-44. doi: 10.1002/syn.21531. Epub 2012 Feb 15.

PMID:
22213370
[PubMed - indexed for MEDLINE]
7.

The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats.

Prins J, Denys DA, Westphal KG, Korte-Bouws GA, Quinton MS, Schreiber R, Groenink L, Olivier B, Korte SM.

Eur J Pharmacol. 2010 May 10;633(1-3):55-61. doi: 10.1016/j.ejphar.2010.02.009. Epub 2010 Feb 12.

PMID:
20153745
[PubMed - indexed for MEDLINE]
8.

Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677.

Popik P, Krawczyk M, Golembiowska K, Nowak G, Janowsky A, Skolnick P, Lippa A, Basile AS.

Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):857-73. Epub 2006 Apr 25.

PMID:
16636898
[PubMed - indexed for MEDLINE]
9.

Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050.

Shaw AM, Boules M, Zhang Y, Williams K, Robinson J, Carlier PR, Richelson E.

Eur J Pharmacol. 2007 Jan 19;555(1):30-6. Epub 2006 Oct 17.

PMID:
17109850
[PubMed - indexed for MEDLINE]
10.

Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.

Skolnick P, Krieter P, Tizzano J, Basile A, Popik P, Czobor P, Lippa A.

CNS Drug Rev. 2006 Summer;12(2):123-34. Review.

PMID:
16958986
[PubMed - indexed for MEDLINE]
11.

Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties.

Tian JW, Jiang WL, Zhong Y, Meng Q, Gai Y, Zhu HB, Hou J, Xing Y, Li YX.

Neuroscience. 2011 Nov 24;196:124-30. doi: 10.1016/j.neuroscience.2011.08.064. Epub 2011 Aug 31.

PMID:
21925241
[PubMed - indexed for MEDLINE]
12.

"Broad spectrum" antidepressants: is more better for the treatment of depression?

Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS.

Life Sci. 2003 Nov 7;73(25):3175-9. Review.

PMID:
14561522
[PubMed - indexed for MEDLINE]
13.

The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity.

Tizzano JP, Stribling DS, Perez-Tilve D, Strack A, Frassetto A, Chen RZ, Fong TM, Shearman L, Krieter PA, Tschöp MH, Skolnick P, Basile AS.

J Pharmacol Exp Ther. 2008 Mar;324(3):1111-26. Epub 2007 Dec 18.

PMID:
18089843
[PubMed - indexed for MEDLINE]
Free Article
14.

Differential BDNF responses of triple versus dual reuptake inhibition in neuronal and astrocytoma cells as well as in rat hippocampus and prefrontal cortex.

Prickaerts J, De Vry J, Boere J, Kenis G, Quinton MS, Engel S, Melnick L, Schreiber R.

J Mol Neurosci. 2012 Sep;48(1):167-75. doi: 10.1007/s12031-012-9802-9. Epub 2012 May 13.

PMID:
22581450
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Effect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring rat.

McMillen BA, Shank JE, Jordan KB, Williams HL, Basile AS.

Alcohol Clin Exp Res. 2007 Nov;31(11):1866-71. Epub 2007 Sep 26.

PMID:
17908267
[PubMed - indexed for MEDLINE]
16.

Pharmacological and behavioral analysis of the effects of some bivalent ligand-based monoamine reuptake inhibitors.

Tamiz AP, Bandyopadhyay BC, Zhang J, Flippen-Anderson JL, Zhang M, Wang CZ, Johnson KM, Tella S, Kozikowski AP.

J Med Chem. 2001 May 10;44(10):1615-22.

PMID:
11334571
[PubMed - indexed for MEDLINE]
17.

[Synthesis and antidepressant activities of aryl alkanol piperidine derivatives].

Zheng YY, Gao K, Weng ZJ, Li JQ.

Yao Xue Xue Bao. 2010 Mar;45(3):324-9. Chinese.

PMID:
21351508
[PubMed - indexed for MEDLINE]
18.

The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents.

Dutta AK, Gopishetty B, Gogoi S, Ali S, Zhen J, Reith M.

Eur J Pharmacol. 2011 Dec 5;671(1-3):39-44. doi: 10.1016/j.ejphar.2011.09.162. Epub 2011 Sep 24.

PMID:
21963455
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition.

Paterson NE, Balci F, Campbell U, Olivier BE, Hanania T.

J Psychopharmacol. 2011 Oct;25(10):1357-64. doi: 10.1177/0269881110364272. Epub 2010 Mar 19.

PMID:
20305042
[PubMed - indexed for MEDLINE]
20.

Preclinical pharmacology of F-98214-TA, a novel potent serotonin and norepinephrine uptake inhibitor with antidepressant and anxiolytic properties.

Artaiz I, Zazpe A, Innerárity A, Del Olmo E, Díaz A, Ruiz-Ortega JA, Castro E, Pena R, Labeaga L, Pazos A, Orjales A.

Psychopharmacology (Berl). 2005 Nov;182(3):400-13. Epub 2005 Oct 19.

PMID:
16032410
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk